Tuberculous lymphadenopathy: A multicentre operational study of 6-month thrice weekly directly observed treatment

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 2, 2013, Pages

  Jindal, S K ^a   Aggarwal, A N ^a   Gupta, D ^a   Ahmed, Z ^b   Gupta, K B ^c   Janmeja, A K ^d   Kashyap, S ^e   Singh, M ^a   Mohan, A ^f   Whig, J ^g  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

^c POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^d GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

^e INDIRA GANDHI MEDICAL COLLEGE   (India)

^f SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

^g DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Directly observed treatment; Intermittent therapy; Lymphadenopathy; Revised National Tuberculosis Control Programme; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL OBSERVATION; CONTROLLED STUDY; DIRECTLY OBSERVED TREATMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG THERAPY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOUS LYMPHADENITIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, LYMPH NODE; YOUNG ADULT;

EID: 84872357219     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0333     Document Type: Article

References (35)

1. Lazarus A A, Thilagar B. Tuberculous lymphadenitis. Dis Mon 2007; 53: 10-15. (Pubitemid 46073960)
2. Maltezou H C, Spyridis P, Kafetzis D A. Extra-pulmonary tuberculosis in children. Arch Dis Child 2000; 83: 342-346.
3. TB India 2011. Annual status report. New Delhi, India: Revised National Tuberculosis Control Programme, Government of India, 2011. http://www.tbcindia. nic.in Accessed December 2012.
4. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003.
5. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
6. Jawahar M S, Rajaram K, Sivasubramanian S, et al. Treatment of lymph node tuberculosis - a randomized clinical trial of two 6-month regimens. Trop Med Int Health 2005; 10: 1090-1098. (Pubitemid 41641187)
7. Rani B. Fully intermittent six-month regimens for pulmonary tuberculosis in South India. Indian J Tuberc 1991; 38: 51-53.
8. Balasubramanian R, Ramachandran R. Management of nonpulmonary forms of tuberculosis: review of TRC studies over two decades. Indian J Pediatr 2000; 67 (Suppl 2): 34-40.
9. Chang K C, Leung C C, Grosset J, Yew W W. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: 997-1007.
10. Menon P R, Lodha R, Sivanandan S, Kabra S K. Intermittent or daily short course chemotherapy for tuberculosis in children: meta-analysis of randomized controlled trials. Indian Pediatr 2010; 47: 67-73.
11. Caminero J A, Fuentes Z M, Martín T Y, et al. A 6-month regimen for EPTB with intermittent treatment in the continuation phase: a study of 679 cases. Int J Tuberc Lung Dis 2005; 9: 890-895. (Pubitemid 41139648)
12. Nidhi P, Sapna T, Shalini M, Kumud G. FNAC in tuberculous lymphadenitis: experience from a tertiary level referral center. Indian J Tuberc 2011; 58: 102-107.
13. Fontanilla J M, Barnes A, Von Reyn C F. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis 2011; 53: 555-562.
14. Balaji J, Sundaram S S, Rathinam S N, Rajeswari P A, Kumari M L. Fine-needle aspiration cytology in childhood TB lymphadenitis. Indian J Pediatr 2009; 76: 1241-1246.
15. Annam V, Kulkarni M H, Puranik R B. Clinicopathologic profile of significant cervical lymphadenopathy in children aged 1-12 years. Acta Cytol 2009; 53: 174-178.
16. Blaikley J F, Khalid S, Ormerod L P. Management of peripheral lymph node tuberculosis in routine practice: an unselected 10-year cohort. Int J Tuberc Lung Dis 2011; 15: 375-378.
17. Donald P R. The chemotherapy of tuberculous lymphadenopathy in children. Tuberculosis 2010; 90: 213-224.
18. Kandala V, Kalagani Y, Kondapalli N R, Kandala M. Directly observed treatment short course in immunocompetent patients of tuberculous cervical lymphadenopathy treated in Revised National Tuberculosis Control Programme. Lung India 2012; 29: 109-113.
19. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
20. Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare. TB India 2011. New Delhi, India: Government of India, 2012.
21. Lin C B, Tang M, Hsu A H, Miu W C, Lee Y S, Lee J J. Pilot study of twice-weekly therapy for pulmonary tuberculosis in Taiwan. J Formos Med Assoc 2011; 110: 438-445.
22. Krogh K, Suren P, Mengshoel A T, Brandtzaeg P. Tuberculosis among children in Oslo, Norway, from 1998 to 2009. Scand J Infect Dis 2010; 42: 866-872.
23. Ige O M, Akindele M O. Five-year review of treatment outcome of directly observed therapy (DOT) for re-treatment pulmonary tuberculosis patients in UCH, Ibadan, Nigeria. Afr J Med Sci 2011; 40: 15-21.
24. Goyal J P, Shah V B, Kukkar S R. Consensus statement on childhood tuberculosis. Indian Pediatr 2010; 47: 41-55.
25. Indumathi C K, Prasanna K K, Dinakar C, Shet A, Lewin S. Intermittent short course therapy for pediatric tuberculosis. I ndian Pediatr 2010; 47: 93-96.
26. Jain S K, Aggarwal J K, Rajpal S, Baveja U. Prevalence of HIV infection among tuberculosis patients in Delhi - a sentinel surveillance study. Indian J Tuberc 2000; 47: 21.
27. Mehrotra R, Chaudhary M K, Singh M. HIV seroprevalence in patients with tuberculosis in Allahabad, North India. Indian J Pathol Microbiol 2006; 49: 302-306. (Pubitemid 44276722)
28. Ramzan M, Ali S M, Malik A, Zaka-ur-Rab Z, Shahab T. Frequency of HIV infection amongst children with disseminated tuberculosis and tuberculous meningitis in Aligarh (North I ndia) - a low HIV prevalence area. J Coll Physicians Surg Pak 2009; 19: 566-569.
29. Ramachandran R, Datta M, Subramani R, Baskaran G, Paramasivan C N, Swaminathan S. Seroprevalence of human immunodeficiency virus (HIV) infection among tuberculosis patients in Tamil Nadu. Indian J Med Res 2003; 118: 147-151. (Pubitemid 38008128)
30. Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore) 2005; 84: 350-362. (Pubitemid 41668934)
31. British Thoracic Society Research Committee. Six-months versus nine-months chemotherapy for tuberculosis of lymph nodes: preliminary results. Respir Med 1992; 86: 15-19.
32. Campbell I A, Ormerod L P, Friend P A, Jenkins R, Prescott J. Six months versus nine months chemotherapy for tuberculosis of lymph nodes: final results. Respir Med 1993; 87: 621-623. (Pubitemid 23350171)
33. Wang Y Y, Liabsuetrakul T, Chongsuvivatwong V, et al. Under- and over-consumption of intermittent TB treatment among rural TB patients in south-west China. Int J Tuberc Lung Dis 2007; 11: 1345-1351.
34. Wong M Y, Leung C C, Tam C M, Lee S N. Directly observed treatment of tuberculosis in Hong Kong. Int J Tuberc Lung Dis 2005; 9: 443-449. (Pubitemid 40524037)
35. Cox H S, Morrow M, Deutschmann P W. Long-term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008; 336: 484-487. (Pubitemid 351350598)